Extended-duration rivaroxaban cuts thromboembolic events in medically ill patients
30 Jun 2020
byStephen Padilla
Extended-duration thromboprophylaxis with low-dose rivaroxaban in at-risk medically ill patients discharged from the hospital significantly reduces fatal and major thromboembolic events, including symptomatic venous thromboembolism (VTE), myocardial infarction (MI), nonhaemorrhagic stroke, and cardiovascular (CV) death, with no significant increase in major bleeding, compared with placebo, a study has shown.